KCTD5 and pancreatic adenocarcinoma: The results showed that KCTD5 was highly expressed in glioblastoma (P < 0.001), head and neck squamous carcinoma (P < 0.001), hepatocellular carcinoma (P < 0.001), lung adenocarcinoma (P < 0.001), pancreatic adenocarcinoma (P < 0.001), clear cell RCC (P < 0.001), and uterine corpus endometrial carcinoma (UCEC) (P < 0.05) (Supplementary Fig. 1).